According to the latest report by IMARC Group, titled "Inhalation Anesthesia Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028," the global inhalation anesthesia market size reached US$ 1.6 Billion in 2022. Inhalation anesthesia refers to a type of anesthetic that is administered in the lungs through an inhalation procedure. It can induce and maintain general anesthesia and sedation, due to which it is typically used during surgical procedures, especially when it is difficult to identify an intravenous route. Inhalation anesthesia includes enflurane, sevoflurane, desflurane, isoflurane, and volatile liquids, such as halothane, as standard drugs. These agents can cause a decrease in arterial blood pressure, respiratory depression, and an increase in cerebral blood flow, resulting in controlled pain and regulated breathing, blood pressure levels, blood flow, and heart rate and rhythm. As compared to traditionally used intravenous variants, inhalation anesthesia does not accumulate in the body and allows precise control over the sedative state of the patient at cost-effective rates. As a resuIt, inhalation anesthesia is extensively used in surgical centers and ambulatory and hospital settings by healthcare practitioners to numb the sensation in specific body parts and eliminate severe pain during surgical procedures.
Global Inhalation Anesthesia Market Trends:
The increasing prevalence of chronic ailments, such as cardiovascular, gastrointestinal, neurological, respiratory, and degenerative disorders, and the rising instances of road accidents across the globe are primarily driving the market growth. In line with this, the shifting inclination towards minimally invasive (MI) treatments and the ongoing number of surgical procedures, such as laparoscopic, cosmetic surgery, and microsurgery, are acting as another growth-inducing factor. Additionally, the increasing instances of sports-related injuries and escalating frequencies of orthopedic operations, such as ligament and other soft tissue repair procedures, are further intensifying product usage in the healthcare sector. Moreover, the extensive use of sevoflurane and other ether-based inhalation anesthetic agents with low pungency and non-irritant odor in ambulatory healthcare centers for patients dealing with asthma or sensitive air passages is impelling the market growth. Furthermore, the recent development of anesthesia recycling systems for isolating anesthetic compounds from hospital vents and operating rooms is favoring the market growth. Apart from this, the introduction of novel product variants with enhanced compatibility and minimal side effects to promote the effective treatment of patients sensitive to anesthetic agents is positively impacting the market growth. Looking forward, the market value is projected to reach 1.9 Billion by 2028, expanding at a CAGR of 3.4% during 2023-2028.
- On the basis of the product type, the market is segregated into desflurane, sevoflurane, isoflurane, and others.
- Based on the application, the market has been bifurcated into induction and maintenance.
- On the basis of the end user, the market has been divided into hospitals, ambulatory surgical centers, and others.
- Region-wise, the market has been segmented into North America (the United States and Canada), Asia-Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others), Latin America (Brazil, Mexico, and others), and Middle East and Africa.
- The competitive landscape of the market has also been examined, with some of the key players being Abbvie Inc., Baxter International Inc., Fresenius SE & Co. KGaA, Halocarbon Products Corporation, Hikma Pharmaceuticals PLC, Lunan Pharmaceutical Group Co. Ltd, Merck KGaA, Piramal Enterprises Ltd. and Troikaa Pharmaceuticals Ltd.
|Base Year of the Analysis
||Product, Application, End User, Region
|| Asia Pacific, Europe, North America, Latin America, Middle East and Africa
||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
||Abbvie Inc., Baxter International Inc., Fresenius SE & Co. KGaA, Halocarbon Products Corporation, Hikma Pharmaceuticals PLC, Lunan Pharmaceutical Group Co. Ltd, Merck KGaA, Piramal Enterprises Ltd. and Troikaa Pharmaceuticals Ltd.
||10% Free Customization
|Report Price and Purchase Option
||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support
||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
134 N 4th St.
Brooklyn, NY 11249, USA
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800